Plant Bioscience
Procarta Biosystems is a UK based biotech company that has discovered a new type of antimicrobial that kills bacteria, including multidrug-resistant (MDR) Gram-negative strains, by blocking their gene expression through a novel mechanism. The Company is developing a pipeline of these antibacterial agents discovered using its proprietary Oligonucleotide Antimicrobial Discovery platform. The lead asset, PRO-202, targeting CRE bacteria, is in preclinical development to treat complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Infections caused by MDR bacteria are correlated with increased deaths, prolonged stay in hospital and pose a major threat to global public health. Procarta aims to revolutionise the treatment of serious and life-threatening infection through disruptive innovation. Our goal is to radically improve patient well-being and aid in the global fight against AMR. The latest funding comes in alongside existing investors UKI2S, Wren Capital, Meltwind, Development Bank Wales and Morningside.
About Plant Bioscience
Founded
2007Estimated Revenue
$1M-$10MEmployees
11-50Funding / Mkt. Cap
$1MCategory
Industry
BiotechnologyLocation
City
NorwichState
NorfolkCountry
United KingdomPlant Bioscience
Find your buyer within Plant Bioscience